预防"新"痴呆症的新兴技术:加拿大背景下的模糊乐观
Annette Leibing1, Cynthia Lazzaroni2, Niklas Petersen3
1Faculty of Nursing, University of Montreal, Montreal, Canada.
Medical anthropology
|August 8, 2023
概括
专家们对数字痴呆症预防技术表现出希望和犹. 他们警告不要过分强调个别技术解决方案,强调更广泛的公共卫生和环境需求,以有效预防痴呆症.
科学领域:
- 老年学是指老年学的学科.
- 数字健康数字健康
- 公共卫生 公共卫生
背景情况:
- 数字技术为预防痴呆症提供了潜在的潜力.
- 专家对这些工具的看法分为乐观和怀疑.
- 人们对过度依赖单个技术干预存在担忧.
研究的目的:
- 分析有关预防数字痴呆症的专家观点.
- 探讨不同专家意见的根本原因.
- 识别当前方法的潜在风险和局限性.
主要方法:
- 对预防痴呆症的老年技术专家意见的定性分析.
- 检查技术乐观和怀疑之间的相互作用.
- 对有关个人与公共卫生干预措施的担忧进行主题分析.
主要成果:
- 专家们表现出"老技术乐观"与显著的犹.
- 一个关键的问题是痴呆症预防的复杂性超出了个人技术.
- 有一种"残酷的乐观主义"的风险,这种乐观主义的根源在于"支持自主权"的幻想.
结论:
- 数字痴呆症预防工具看起来有前途,但需要谨慎实施.
- 需要采取平衡的方法,将技术与公共卫生政策和环境考虑相结合.
- 通过技术"支持自主"的概念可能掩盖了痴呆症护理中更深层次的社会挑战.
更多相关视频
07:31A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
Published on: February 13, 2020
7.0K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.4K
相关概念视频
Cognitive Development During Adulthood
157
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
157
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
